Search

everythinglearnresearchcommunity

for

Search:↓

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.

Chemotherapy-induced hair loss may be linked to immune system changes, and certain treatments could help but need careful use.

Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Silicate-based therapy may help treat inflammatory heart disease by reducing immune inflammation.

Blocking certain proteins on immune cells may help treat alopecia areata.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.

PTH-CBD could help prevent and treat hair loss caused by chemotherapy in mice.

Enhancing Tregs can protect against alopecia areata.

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.

Belatacept may be a promising treatment for alopecia areata.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

Promising cancer treatments were found, but the manufacturer closed.

Expanding CD4+ Tregs can stop hair loss in alopecia areata.

CDK4/6 inhibitors can protect hair cells from chemotherapy damage.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Controlled delivery of specific RNA and IL-4 restored hair growth in mice with autoimmune alopecia.

Blocking both P-cadherin and c-Met can effectively stop head and neck cancer growth.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Targeted immunotherapy could be a promising new treatment for hair regrowth.

Blocking mTORC1 reduces skin tumor growth in mice.